503 related articles for article (PubMed ID: 11838854)
1. Rheumatologists' adherence to guidelines for misoprostol use in patients at high risk for nonsteroidal antiinflammatory drug gastropathy.
Cibere J; Sibley JT; Haga M
J Rheumatol; 2002 Feb; 29(2):339-46. PubMed ID: 11838854
[TBL] [Abstract][Full Text] [Related]
2. Complications of nonsteroidal antiiflammatory drug gastropathy and use of gastric cytoprotection: experience at a tertiary care health center.
Bakowsky VS; Hanly JG
J Rheumatol; 1999 Jul; 26(7):1557-63. PubMed ID: 10405945
[TBL] [Abstract][Full Text] [Related]
3. Underutilization of preventive strategies in patients receiving NSAIDs.
Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
[TBL] [Abstract][Full Text] [Related]
4. Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines.
Laine L; Connors L; Griffin MR; Curtis SP; Kaur A; Cannon CP
Aliment Pharmacol Ther; 2009 Oct; 30(7):767-74. PubMed ID: 19594486
[TBL] [Abstract][Full Text] [Related]
5. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
Goldstein JL; Huang B; Amer F; Christopoulos NG
Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480
[TBL] [Abstract][Full Text] [Related]
6. Risk factors for serious nonsteroidal-induced gastrointestinal complications: regression analysis of the MUCOSA trial.
Simon LS; Hatoum HT; Bittman RM; Archambault WT; Polisson RP
Fam Med; 1996 Mar; 28(3):204-10. PubMed ID: 8900554
[TBL] [Abstract][Full Text] [Related]
7. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients.
Wolfe F; Hawley DJ
J Rheumatol; 2000 Jul; 27(7):1668-73. PubMed ID: 10914849
[TBL] [Abstract][Full Text] [Related]
8. Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals.
Greenberg JD; Bingham CO; Abramson SB; Reed G; Kishimoto M; Hinkle K; Kremer J
Arthritis Rheum; 2006 Aug; 55(4):543-50. PubMed ID: 16874798
[TBL] [Abstract][Full Text] [Related]
9. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
[TBL] [Abstract][Full Text] [Related]
10. Cost effectiveness of replacing diclofenac with a fixed combination of misoprostol and diclofenac in patients with rheumatoid arthritis.
Kristiansen IS; Kvien TK; Nord E
Arthritis Rheum; 1999 Nov; 42(11):2293-302. PubMed ID: 10555023
[TBL] [Abstract][Full Text] [Related]
11. An evidence-based approach to prescribing nonsteroidal antiinflammatory drugs. Third Canadian Consensus Conference.
Tannenbaum H; Bombardier C; Davis P; Russell AS;
J Rheumatol; 2006 Jan; 33(1):140-57. PubMed ID: 16331802
[TBL] [Abstract][Full Text] [Related]
12. Gastrointestinal prophylactic therapy among patients with arthritis treated by rheumatology specialists.
Garcia EB; Michaud K; Wolfe F
J Rheumatol; 2006 Apr; 33(4):779-84. PubMed ID: 16511939
[TBL] [Abstract][Full Text] [Related]
13. Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications.
Goldstein JL; Howard KB; Walton SM; McLaughlin TP; Kruzikas DT
Clin Gastroenterol Hepatol; 2006 Nov; 4(11):1337-45. PubMed ID: 17088110
[TBL] [Abstract][Full Text] [Related]
14. Impact of selective cyclooxygenase-2 inhibitors on anti-ulcer medication and non-steroidal anti-inflammatory drug use in patients with rheumatic disease.
Joshua FF; Oakley SP; Major GA
Intern Med J; 2004 Apr; 34(4):153-61. PubMed ID: 15086694
[TBL] [Abstract][Full Text] [Related]
15. Use of physician education and computer alert to improve targeted use of gastroprotection among NSAID users.
Coté GA; Rice JP; Bulsiewicz W; Norvell JP; Christensen K; Bobb A; Postelnick M; Howden CW
Am J Gastroenterol; 2008 May; 103(5):1097-103. PubMed ID: 18477341
[TBL] [Abstract][Full Text] [Related]
16. Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs.
Ray WA; Chung CP; Stein CM; Smalley WE; Hall K; Arbogast PG; Griffin MR
Gastroenterology; 2007 Sep; 133(3):790-8. PubMed ID: 17854591
[TBL] [Abstract][Full Text] [Related]
17. The cost-effectiveness of misoprostol in preventing serious gastrointestinal events associated with the use of nonsteroidal antiinflammatory drugs.
Maetzel A; Ferraz MB; Bombardier C
Arthritis Rheum; 1998 Jan; 41(1):16-25. PubMed ID: 9433865
[TBL] [Abstract][Full Text] [Related]
18. Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care.
Wolfe F; Zhao S; Pettitt D
J Rheumatol; 2004 Jun; 31(6):1143-51. PubMed ID: 15170928
[TBL] [Abstract][Full Text] [Related]
19. Inadequate prevention of NSAID-induced gastrointestinal events.
Herings RM; Goettsch WG
Ann Pharmacother; 2004 May; 38(5):760-3. PubMed ID: 15031416
[TBL] [Abstract][Full Text] [Related]
20. Prevention of gastrointestinal complications associated with nonsteroidal antiinflammatory drugs.
Agrawal NM; Aziz K
J Rheumatol Suppl; 1998 May; 51():17-20. PubMed ID: 9596550
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]